- •Patients with recurrent ovarian cancer (OC) who responded to rucaparib treatment in Study 10 and ARIEL2 were characterized.
- •Duration of response (DOR) was used to group long- (≥1 y), intermediate- (6 mo to <1 y), and short-term responders (<6 mo).
- •The majority of long- and intermediate-term responders with BRCA wild-type OC had high genome-wide loss of heterozygosity.
- •BRCA structural variants were common in long-term responders and associated with longer DOR than other alteration types.
- •Our analyses show that reversion-resistant BRCA structural variants contribute to extended DOR to PARP inhibitor therapy.
To describe molecular and clinical characteristics of patients with high-grade recurrent ovarian carcinoma (HGOC) who had long-term responses to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib.
This post hoc analysis pooled patients from Study 10 (NCT01482715; Parts 2A and 2B; n = 54) and ARIEL2 (NCT01891344; Parts 1 and 2; n = 491). Patients with investigator-assessed complete or partial response per RECIST were classified based on duration of response (DOR): long (≥1 year), intermediate (6 months to <1 year), or short (<6 months). Next-generation sequencing was used to detect deleterious mutations and loss of heterozygosity (LOH) in tumors.
Overall, 25.3% (138/545) of enrolled patients were responders. Of these, 27.5% (38/138) had long-term responses; 28.3% (39/138) were intermediate- and 34.8% (48/138) were short-term responders. Most of the long-term responders harbored a BRCA1 or BRCA2 (BRCA) mutation (71.1%, 27/38), and BRCA structural variants were most frequent among long-term responders (14.8%; 4/27). Responders with HGOC harboring a BRCA structural variant (n = 5) had significantly longer DOR than patients with other mutation types (n = 81; median not reached vs 0.62 years; HR, 0.21; 95% CI, 0.10–0.43; unadjusted p = 0.014). Among responders with BRCA wild-type HGOC, most long- and intermediate-term responders had high genome-wide LOH: 81.8% (9/11) and 76.9% (10/13), respectively, including 7 with deleterious RAD51C, RAD51D, or CDK12 mutations.
Among patients who responded to rucaparib, a substantial proportion achieved responses lasting ≥1 year. These analyses demonstrate the relationship between DOR to PARP inhibitor treatment and molecular characteristics in HGOC, such as presence of reversion-resistant BRCA structural variants.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Gynecologic Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.Nature. 2005; 434: 913-917
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.Nature. 2005; 434: 917-921
- Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.Int. J. Gynecol. Cancer. 2019; 29: 1396-1404
- Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from study 10 and ARIEL2.Gynecol. Oncol. 2017; 147: 267-275
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial.Lancet Oncol. 2017; 18: 75-87
- A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors.Clin. Cancer Res. 2017; 23: 4095-4106
- Molecular and clinical determinants of response and resistance to the PARP inhibitor rucaparib for recurrent ovarian cancer treatment in ARIEL2 (parts 1 and 2).Nat. Commun. 2021; 12: 2487
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2017; 390: 1949-1961
- Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial.J. Clin. Oncol. 2019; 37: 2968-2973
- Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.Lancet Oncol. 2016; 17: 1579-1589
- Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.Oncotarget. 2017; 8: 47154-47160
- Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization.Clin. Cancer Res. 2017; 23: 4086-4094
- BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma.Cancer Discov. 2019; 9: 210-219
- Homologous recombination DNA repair pathway disruption and retinoblastoma protein loss are associated with exceptional survival in high-grade serous ovarian cancer.Clin. Cancer Res. 2018; 24: 569-580
- Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma.Cancer Discov. 2017; 7: 984-998
- Whole–genome characterization of chemoresistant ovarian cancer.Nature. 2015; 521: 489-494
- Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.Breast Cancer Res. 2014; 16: 211
- NCI Term Browser.CTCAE, 2017Accessed date: January 26, 2021)
- Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.Proc. Natl. Acad. Sci. U. S. A. 2010; 107: 12629-12633
- Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.Nat. Commun. 2018; 9: 3970
- A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.PLoS Comput. Biol. 2018; 14e1005965
- Exceptional response to olaparib in a patient with recurrent ovarian cancer and an entire BRCA1 germline gene deletion.J. Natl. Compr. Cancer Netw. 2020; 18: 223-228
- PARP inhibitor resistance mechanisms and implications for post-progression combination therapies.Cancers. 2020; 12: 2054
Published online: September 30, 2021
Accepted: August 30, 2021
Received in revised form: August 26, 2021
Received: May 20, 2021
© 2021 Elsevier Inc. All rights reserved.